Remibrutinib targets Bruton’s tyrosine kinase (BTK), an intracellular signaling node in B cells and myeloid cells that contributes to immune activation and neuroinflammation in multiple sclerosis.
Related Analysis
Want the news story behind this science? Read my analysis of Novartis’ positive Phase 3 REMODEL results for remibrutinib in relapsing multiple sclerosis.
Science at a Glance
Remibrutinib is an oral covalent BTK inhibitor that suppresses signaling in B cells and myeloid cells without directly depleting B cells. Novartis reported positive results from both Phase 3 REMODEL trials in relapsing multiple sclerosis (RMS) and plans global regulatory submissions. (Novartis REMODEL)
| Therapy | Company | Mechanism | MS status |
|---|---|---|---|
| Remibrutinib | Novartis | Covalent BTK inhibitor | RMS Phase 3 positive |
| Fenebrutinib | Roche | Reversible, non-covalent BTK inhibitor | RMS & PPMS Phase 3 positive |
| Tolebrutinib (Cenrifki) | Sanofi | Brain-penetrant covalent BTK inhibitor | EU approved for nrSPMS |
| Ocrevus (ocrelizumab) | Roche | Anti-CD20 B-cell depletion | Approved for RMS & PPMS |
| Kesimpta (ofatumumab) | Novartis | Anti-CD20 B-cell depletion | Approved for RMS |
The BTK inhibitor race is therefore no longer defined by the target alone. Binding mode, CNS penetration, efficacy across MS subtypes and long-term safety are becoming key competitive differentiators. (BTK inhibitor review)
Why BTK Matters in Multiple Sclerosis
Multiple sclerosis is an immune-mediated disease of the central nervous system in which inflammation damages myelin and axons in the brain, optic nerves and spinal cord.
Bruton’s tyrosine kinase (BTK) is an intracellular tyrosine kinase expressed predominantly in B cells and myeloid cells, including macrophages and microglia.
In B cells, activation of the B-cell receptor (BCR) engages BTK signaling that contributes to B-cell activation, proliferation, cytokine production and antigen presentation. In myeloid cells, BTK also participates in Fc-receptor-mediated inflammatory signaling. (BTK biology in MS)
At the protein-signaling level, the pathway can be simplified as:
BCR / Fc receptor activation
→ BTK
→ PLCγ2
→ DAG + IP3
From there, signaling branches into multiple pathways:
DAG → PKCβ → NF-κB
IP3 → intracellular Ca²⁺ ↑ → calcineurin → NFAT
and
RAS → RAF → MEK → ERK
Together, these pathways regulate immune-cell activation, cytokine production, survival and inflammatory gene expression.
How Remibrutinib Interrupts the Signal
Remibrutinib binds BTK and inhibits its kinase activity, reducing downstream signaling before these inflammatory pathways fully activate.
This is fundamentally different from eliminating the B cell itself.
Remibrutinib inhibits BTK signaling in immune cells while leaving the B-cell compartment largely intact, potentially reducing B-cell activation and inflammatory signaling from myeloid cells at the same time.
That dual biology is particularly relevant to MS because B cells contribute strongly to relapsing inflammatory activity, while microglia and other CNS-resident myeloid cells are increasingly associated with chronic neuroinflammation and disability progression.
Remibrutinib, fenebrutinib and tolebrutinib all inhibit BTK, but differ in binding mode, CNS pharmacology and clinical development profile.
Three BTK Inhibitors, Three Different Profiles
The three leading BTK inhibitors target the same kinase but differ substantially in pharmacology and clinical positioning.
Remibrutinib is a covalent BTK inhibitor developed by Novartis. Its Phase 3 program currently centers on RMS, and Novartis has highlighted its high selectivity together with a favorable safety profile in REMODEL. (Novartis REMODEL)
Fenebrutinib is a reversible, non-covalent BTK inhibitor developed by Roche. In the Phase 3 FENhance 1 and 2 trials, fenebrutinib reduced annualized relapse rate by approximately 51.1% and 58.5% versus teriflunomide, respectively. Roche has also reported positive Phase 3 results in primary progressive MS (PPMS). (Roche fenebrutinib)
Tolebrutinib is a brain-penetrant covalent BTK inhibitor developed by Sanofi. Its distinguishing feature is high CNS exposure intended to reach BTK signaling in resident microglia, and it is approved in the European Union for non-relapsing secondary progressive MS (nrSPMS). (Sanofi Cenrifki)
Clinical Validation in REMODEL
Novartis evaluated remibrutinib against teriflunomide in the identical Phase 3 REMODEL-1 and REMODEL-2 trials, which together enrolled approximately 2,000 adults with relapsing multiple sclerosis.
Both REMODEL trials met their primary endpoint, with remibrutinib significantly reducing annualized relapse rate compared with teriflunomide. Remibrutinib also showed superiority on key MRI measures, while disability progression results showed a favorable overall trend. (REMODEL Phase 3)
Importantly, Novartis reported no liver safety signal and no cases meeting Hy’s Law criteria across the two Phase 3 studies.
Detailed numerical ARR results have not yet been publicly presented, so the current evidence remains positive topline Phase 3 data rather than a complete efficacy dataset.
BTK Inhibition vs Anti-CD20 B-Cell Depletion
Anti-CD20 antibodies such as Ocrevus and Kesimpta are established high-efficacy therapies in multiple sclerosis, but their mechanism differs fundamentally from BTK inhibition.
| BTK inhibitors | Anti-CD20 antibodies | |
|---|---|---|
| Primary approach | Intracellular signaling suppression | B-cell depletion |
| B-cell population | Largely preserved | CD20-positive B cells reduced |
| Myeloid / microglial signaling | Potentially affected | Not a primary target |
| Examples | Remibrutinib, fenebrutinib, tolebrutinib | Ocrevus, Kesimpta |
| Key concept | Suppress the signal | Remove the cell |
Anti-CD20 therapy can strongly suppress MS disease activity, but sustained B-cell depletion may lower immunoglobulin levels and increase infection risk. BTK inhibitors instead aim to modulate pathogenic immune signaling without directly eliminating the B-cell population. (BTK vs anti-CD20)
BTK inhibitors suppress signaling within B cells and myeloid cells, whereas anti-CD20 antibodies primarily reduce disease activity by depleting CD20-positive B cells.
BP Science View
The scientific appeal of BTK inhibition in multiple sclerosis is that it may address both adaptive and innate immune biology. B cells are important drivers of relapsing inflammation, while microglia and other CNS-resident myeloid cells contribute to chronic neuroinflammation and disability progression.
This also differentiates BTK inhibitors from anti-CD20 antibodies such as Ocrevus and Kesimpta. Anti-CD20 therapies primarily deplete CD20-positive B cells, whereas BTK inhibitors suppress intracellular signaling in B cells and myeloid cells without directly eliminating the B-cell compartment. That distinction may matter for long-term immune preservation and for targeting inflammation within the CNS. (BTK vs anti-CD20)
The BTK inhibitor class itself is becoming increasingly differentiated. Remibrutinib is a covalent inhibitor with positive Phase 3 RMS data and no liver safety signal reported in REMODEL; fenebrutinib uses reversible non-covalent binding and has positive Phase 3 data in both RMS and PPMS; and tolebrutinib is a brain-penetrant covalent inhibitor already approved in the EU for non-relapsing SPMS. (Novartis REMODEL, Roche fenebrutinib, Sanofi Cenrifki)
In my view, remibrutinib’s Phase 3 success is important, but BTK inhibition alone will not determine the winner. The competitive question will increasingly be which pharmacological profile delivers the strongest combination of relapse control, disability benefit, CNS activity and long-term safety.
About BP Science
BP Science explains the biology and mechanisms behind emerging biopharmaceutical technologies, connecting molecular science with clinical and competitive development.
Have a question about my interpretation or another angle you’d like to discuss? Leave a comment — I’d be happy to hear your thoughts.
Leave a Reply